LEAP-008:仑伐替尼联合帕博利珠单抗用于经抗程序性细胞死亡蛋白1或抗程序性细胞死亡配体1联合铂类化疗后进展的转移性非小细胞肺癌
LEAP-008是一项开放标签、随机、3期研究,比较仑伐替尼联合帕博利珠单抗与多西他赛在经抗PD-1/PD-L1治疗和含铂化疗后进展的转移性NSCLC患者中的疗效。研究纳入422例患者,随机分配至联合组(n=185)、多西他赛组(n=189)或仑伐替尼单药组(n=48)。联合组与多西他赛组的中位PFS分别为5.6个月和4.2个月(HR 0.89,95%CI 0.70-1.12;p=0.164),中位OS分别为11.3个月和12.0个月(HR 0.98,95%CI 0.78-1.23;p=0.434),联合治疗未改善疗效。
要点
- 仑伐替尼联合帕博利珠单抗对比多西他赛未显著改善PFS(HR 0.89,p=0.164)和OS(HR 0.98,p=0.434)。
- 联合组≥3级治疗相关不良事件发生率为59.7%,多西他赛组为48.6%,仑伐替尼单药组为57.4%。
- 两组健康相关生活质量评分相似,未观察到非预期安全性信号。
核心结论
- 在经抗PD-1/PD-L1治疗和含铂化疗后进展的IV期NSCLC患者中,仑伐替尼联合帕博利珠单抗对比多西他赛未改善疗效。
- 未观察到非预期安全性信号,该患者人群需要更有效的治疗。
研究设计与样本
- LEAP-008(NCT03976375)是一项开放标签、随机、3期研究。
- 患者按4:4:1随机分配至仑伐替尼20 mg每日一次联合帕博利珠单抗200 mg每3周一次(最多35周期)、多西他赛75 mg/m2每3周一次或仑伐替尼24 mg每日一次。
- 主要终点为盲态独立中心审查按RECIST 1.1评估的OS和PFS;PFS在第二次中期分析时评估优效性,OS在最终分析时评估。
- 共纳入422例患者,联合组185例,多西他赛组189例,仑伐替尼单药组48例。
主要发现
- 联合组中位PFS为5.6个月(95%CI 4.2-6.5),多西他赛组为4.2个月(95%CI 3.2-5.2),HR 0.89(95%CI 0.70-1.12;p=0.164)。
- 联合组中位OS为11.3个月(95%CI 9.4-13.2),多西他赛组为12.0个月(95%CI 9.6-13.7),HR 0.98(95%CI 0.78-1.23;p=0.434)。
- 联合组、多西他赛组和仑伐替尼单药组的治疗相关不良事件发生率分别为91.7%、91.0%和89.4%;3-5级治疗相关不良事件发生率分别为59.7%、48.6%和57.4%。
- 各治疗组间健康相关生活质量评分相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: LEAP-008 (NCT03976375) was an open-label, randomized, phase 3 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic NSCLC that progressed on anti‒programmed cell death protein 1 or anti‒programmed cell death ligand 1 therapy and platinum-containing chemotherapy. METHODS: Participants were randomized 4:4:1 to once-daily lenvatinib 20 mg plus pembrolizumab 200 mg every 3 weeks (maximum 35 cycles), docetaxel 75 mg/m2 every 3 weeks, or once-daily lenvatinib 24 mg. Primary end points were overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 by central review. The superiority of lenvatinib plus pembrolizumab versus docetaxel was assessed at interim analysis 2 for PFS and final analysis for OS. RESULTS: Participants (N = 422) were randomized to lenvatinib plus pembrolizumab (n = 185), docetaxel (n = 189), or lenvatinib monotherapy (n = 48). The median (95% confidence interval [CI]) PFS was 5.6 (4.2‒6.5) months with lenvatinib plus pembrolizumab and 4.2 (3.2‒5.2) months with docetaxel (hazard ratio, 0.89 [95% CI: 0.70‒1.12]; p = 0.164). The median (95% CI) OS was 11.3 (9.4‒13.2) versus 12.0 (9.6‒13.7) months (hazard ratio, 0.98 [95% CI: 0.78‒1.23]; p = 0.434). Rates of treatment-related adverse events were 91.7%, 91.0%, and 89.4% with lenvatinib plus pembrolizumab, docetaxel, and lenvatinib, respectively; the rates of grade 3 to 5 treatment-related adverse events were 59.7%, 48.6%, and 57.4%. Health-related quality of life scores were similar between treatment arms. CONCLUSION: Lenvatinib plus pembrolizumab did not improve efficacy versus docetaxel in participants with stage IV NSCLC that progressed on anti‒programmed cell death protein 1 or anti-programmed cell death ligand 1 therapy and platinum-containing chemotherapy. There were no unexpected safety signals. More effective therapies are needed for this patient population.
引用
- Leighl NB, Paz-Ares L, Abreu DR, et al. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. J Thorac Oncol. 2025. PMID: 40473109. doi:10.1016/j.jtho.2025.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。